Mrinalini Dey DrMiniDey
2 years 2 months ago
OP0086 #EULAR2024 @RheumNow #EULARBest
Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL
Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action
1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.
Aurelie Najm AurelieRheumo
2 years 2 months ago
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
@RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo
Aurelie Najm AurelieRheumo
2 years 2 months ago
200 millions pts PSO
1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi
2nd line ttmt, IL12-23i 32% & IL-23i 31%
IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs
Can't exclude some channeling bias, but that's a big signal!
@RheumNow OP0010 #EULAR2024 #EULARBest
Aurelie Najm AurelieRheumo
2 years 2 months ago
AMPLIFIED RCT, 300+ pts
ABA NOT (!) superior to ADA
in dual seropositive SE+ MTX IR RA pts
ACR50 rate high in both gps ABA 59% vs ADA 64%
No new safety signal
Defeating the encouraging data from smaller trials
Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl
Dr. John Cush RheumNow
2 years 2 months ago
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.
Annals of the Rheumatic Diseases ARD_BMJ
2 years 2 months ago
What is the origin of pain in difficult to manage axSpA?
1- Inflammation
2- Degenerative
3- Central Nervous System
#EULAR2024
NZ https://t.co/KzATnYN4HG
Aurelie Najm AurelieRheumo
2 years 2 months ago
Ph III RCT SHR0302 JAK1 selective inhibitor in RA
500+ pts
ACR20 wk 24 SHR0302 8mg & 4mg PBO 75% 70% 40%
ACR70 wk 24 SHR0302 8mg & 4mg PBO 31% 22% 7%
Safety similar other JAKi
Abstr#OP0037 #EULAR24 @RheumNow https://t.co/6ZuvT6czo8
Bella Mehta bella_mehta
2 years 2 months ago
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.
Tuhina Neogi, MD, PhD Tuhina_Neogi
2 years 2 months ago
Great 1st #EULAR2024 scientific session: “Asymptomatic” Hyperuricemia — innocent bystander vs. menacing foe. Data re: effects on joints, kidneys, & heart have not supported clear clinical consequences w/ exception of kidney crystal deposition. TIGER Study results eagerly awaited. https://t.co/IPQU3Ww0NA
David Liew drdavidliew
2 years 2 months ago
Final prep in my hotel room for tomorrow’s big #EULAR2024 opening debate: this David up against the metaphorical (if not physical) Goliath, @Janetbirdope.
Data does not adequately justify this JAKi regulatory safety warning, tomorrow I’ll tell you why. Details below ⬇️
@RheumNow https://t.co/rwFtYRlpLY
Dr Gurdeep S Dulay gurdeep_dulay
2 years 2 months ago
#EULAR204
Encouraging Timeline for future potential treatments for #SLE #Lupus
@LUPUSUK @LupusMadrid @Lupus_Chat @LupusEurope https://t.co/SLKc0XCtFq
Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.
Dr Gurdeep S Dulay gurdeep_dulay
2 years 2 months ago
Reminder of relevance of #Rheumatoid factor
⬆️RF also predicts
cardiovascular events ⚠️
⬆️disease activity
❗️Worse outcomes
#EULAR2024 #RF #RA https://t.co/kXwh682ONp
